Pivotal Data Highlights on Myeloproliferative NeoplasmsMyelofibrosis

Activity Goals

Prognosis: CALR MF is a Distinct Entity

Clinical Effect of Founding Driver Mutations in MF

Phase 1b: Panobinostat and Ruxolitinib in MF

Novel Combination: PRM-151 + RUX

ET: Molecular Markers

ET: Impact of Treatment on Molecular Markers

Prognosis and Risk Stratification

Splanchnic Vein Thrombosis

Pivotal Data Highlights on Acute Myeloid LeukemiaFLT3 Inhibition

Phase 2: Efficacy of Quizartinibin Relapsed/ Refractory AML

Quizartinib as a Bridge to HCT in FLT3-ITD(+) AML

Pivotal Data Highlights on Acute Myeloid LeukemiaNew Agents for Older Patients

Phase I/2 Study of Volasertib

Phase 2:Efficacy and Safety of SGI-110

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)